PVG Asset Management Corp Sells 4,143 Shares of Johnson & Johnson (NYSE:JNJ)

PVG Asset Management Corp reduced its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 65.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,225 shares of the company's stock after selling 4,143 shares during the quarter. Johnson & Johnson makes up about 1.4% of PVG Asset Management Corp's holdings, making the stock its 23rd largest position. PVG Asset Management Corp's holdings in Johnson & Johnson were worth $361,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in JNJ. AlphaMark Advisors LLC lifted its holdings in Johnson & Johnson by 5.3% during the 2nd quarter. AlphaMark Advisors LLC now owns 1,517 shares of the company's stock worth $222,000 after purchasing an additional 76 shares in the last quarter. Corundum Group Inc. lifted its holdings in shares of Johnson & Johnson by 28.9% in the second quarter. Corundum Group Inc. now owns 11,067 shares of the company's stock worth $1,618,000 after buying an additional 2,478 shares in the last quarter. Red Door Wealth Management LLC boosted its position in shares of Johnson & Johnson by 4.5% in the second quarter. Red Door Wealth Management LLC now owns 49,458 shares of the company's stock valued at $7,229,000 after acquiring an additional 2,136 shares during the period. Blackston Financial Advisory Group LLC grew its stake in Johnson & Johnson by 201.9% during the second quarter. Blackston Financial Advisory Group LLC now owns 4,275 shares of the company's stock valued at $625,000 after acquiring an additional 2,859 shares in the last quarter. Finally, Welch Group LLC lifted its stake in Johnson & Johnson by 3.2% in the 2nd quarter. Welch Group LLC now owns 337,096 shares of the company's stock worth $49,270,000 after purchasing an additional 10,331 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Trading Down 0.3 %

JNJ stock traded down $0.41 during trading on Thursday, hitting $146.23. 6,174,458 shares of the company traded hands, compared to its average volume of 7,118,662. The company has a 50-day moving average of $157.29 and a 200-day moving average of $156.35. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85. The firm has a market capitalization of $352.07 billion, a PE ratio of 21.28, a P/E/G ratio of 2.66 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm had revenue of $22.47 billion for the quarter, compared to analysts' expectations of $22.17 billion. During the same quarter last year, the business earned $2.66 earnings per share. The business's revenue was up 5.2% on a year-over-year basis. Analysts predict that Johnson & Johnson will post 9.93 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th were paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.39%. The ex-dividend date was Tuesday, November 26th. Johnson & Johnson's dividend payout ratio (DPR) is 71.78%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the firm's stock in a transaction that occurred on Thursday, December 12th. The stock was bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.16% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on JNJ. Cantor Fitzgerald restated an "overweight" rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Morgan Stanley upped their target price on Johnson & Johnson from $169.00 to $175.00 and gave the stock an "equal weight" rating in a research note on Wednesday, October 16th. Royal Bank of Canada lifted their price target on Johnson & Johnson from $178.00 to $181.00 and gave the company an "outperform" rating in a research report on Wednesday, October 16th. Guggenheim raised their target price on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a "neutral" rating in a research note on Wednesday, November 6th. Finally, StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, September 14th. Seven analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and a consensus price target of $174.73.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.